BioStock: DanCann Pharma on Tetra Bio-Pharma’s positive EMA opinion

For Danish DanCann Pharma, Thursday brought good news from its partner Canadian Tetra Bio-Pharma. In May, the two companies signed an exclusive distribution deal regarding three of Tetra Bio-Pharma’s products. Last week, the EMA Committee for Orphan Medicinal Products issued a positive opinion on Tetra Bio-Pharma’s cannabinoid-based drug targeting neuropathic pain. BioStock reached out to DanCann Pharma’s CEO Jeppe Krog Rasmussen for a comment on the possible implications of the positive opinion.

Read the full interview with Jeppe Krog Rasmussen at biostock.se:

https://www.biostock.se/en/2021/10/dancann-pharma-on-tetra-bio-pharmas-positive-ema-opinion/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/